NIH RePORTER
Cure8 regulatory brief
Why This Matters
Researchers are studying a parasite-derived protein (Fh15) that may reduce neutrophil-driven inflammation in sepsis and ulcerative colitis models; this could point toward new anti-inflammatory drug approaches in the future.
The project specifically targets mechanisms (TLR4/NF-κB, NETosis) that are relevant to inflammatory flares in IBD.
Who Should Pay Attention
Researchers and clinicians interested in IBD immunology and drug discovery; patients curious about preclinical research into new anti-inflammatory strategies.
Study Snapshot
Story typeRegulatory
Evidence typeFunded research project
Study statusFunded
Source depthResearch project record
What To Know
This NIH-funded project will test a recombinant helminth-derived protein (Fh15) that the investigators say reduced inflammation in animal models of sepsis and DSS-induced ulcerative colitis.
The team plans experiments to link Fh15’s anti-inflammatory effects to reduced neutrophil extracellular traps (NETs) and extracellular DNA, and to map effects on TLR4/NF-κB signaling in neutrophils using flow cytometry, proteomics, and single-cell RNA sequencing.
The proposal is a funded research project (NIH Reporter entry) describing planned laboratory and animal work rather than clinical results. It emphasizes mechanism studies (NETosis, TLR4/NF-κB, neutrophil activation markers) and includes omics approaches to identify molecules and pathways regulated by Fh15.
If findings hold up, the work could help guide development of new anti-inflammatory drug candidates, but this entry does not report human trial data or proven therapies. Keep the focus on the research: this is a preclinical mechanistic project exploring how a parasite-derived molecule might blunt inflammation in sepsis and colitis models.
It is relevant for understanding potential future drug discovery rather than current treatment choices.
Keep In Mind
This record is an NIH-funded project description (preclinical, mechanistic work) rather than a peer-reviewed paper or clinical trial report. It describes planned lab and animal experiments and does not provide clinical evidence of safety or efficacy in people.
Source Details
Review the original publication for the complete reporting, methods, and context.
Funded research project
Evidence type derived from source or registry metadata.
PublicationNIH RePORTER
AuthorsANA M ESPINO
InstitutionUNIVERSITY OF PUERTO RICO MED SCIENCES
Study typeFunded Research Project
Indexed viaNIH RePORTER
Source typeFunded research record
PublishedSep 1, 2026, 12:00 AM
Content availableResearch project record
Funding disclosed by the source: National Institute of Allergy and Infectious Diseases - R16AI203189 - $149,000
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The causal role of plasma protein ratios in ulcerative colitis: insights from mendelian randomization and single-cell sequencing.
Researchers used genetics plus single-cell sequencing and ELISA to prioritize plasma protein ratios that may causally relate to ulcerative colitis. If validated in larger studies, such biomarkers could help with...
Multi-omics analysis identifies fibroblast IGFBP5 as a key target of anti-TNFα therapy in ulcerative colitis
If validated, IGFBP5 or its downstream pathway could help predict who will not respond to anti-TNF therapy and point to new targets to overcome resistance.
Contribution of the appendix to ulcerative colitis by supplying pathogenic immunoglobulin G-producing cells
If the appendix is a significant source of harmful IgG antibodies in ulcerative colitis, that could help explain why appendectomy sometimes reduces UC risk or severity and might influence future therapies targeting...